- Email: [email protected]
Relapsed and Refractory Hodgkin's Lymphoma: New Avenues?
Hematol Oncol Clin N Am 22 (2008) xi
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA ERRATUM
Relapsed and Refractory Hodgkin’s Lymphoma: New Avenues? George P. Canellos, MD Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
I
n the above article, which published in the October 2007 issue of the Hematology/Oncology Clinics of North America (volume 21, issue 5), please note that further clarification is needed in Table 2 on page 933. The cisplatin dose is 75 mg/m2 on day 1 only, not day 1 and day 8 as appears in the table.
0889-8588/08/$ – see front matter doi:10.1016/j.hoc.2008.06.002
ª 2008 Elsevier Inc. All rights reserved. hemonc.theclinics.com
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA ERRATUM
Relapsed and Refractory Hodgkin’s Lymphoma: New Avenues? George P. Canellos, MD Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
I
n the above article, which published in the October 2007 issue of the Hematology/Oncology Clinics of North America (volume 21, issue 5), please note that further clarification is needed in Table 2 on page 933. The cisplatin dose is 75 mg/m2 on day 1 only, not day 1 and day 8 as appears in the table.
0889-8588/08/$ – see front matter doi:10.1016/j.hoc.2008.06.002
ª 2008 Elsevier Inc. All rights reserved. hemonc.theclinics.com